Director/PDMR Shareholding
05 Dicembre 2023 - 5:01PM
Director/PDMR Shareholding
DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the
“Company”), the AQSE Growth Market quoted clinical decision support
developer and supplier of clinical decision support systems has
received notification and notified the market that on 4 December
2023 Mr Bob Sutcliffe purchased a total of 400,000 Ordinary Shares
in the Company at a price of 2.5p per share on behalf of himself
and others.
One of the other persons acquiring beneficial
ownership of Ordinary Shares as a result of Mr Sutcliffe’s purchase
is David Immelman, the DXS Chief Executive, who has acquired a
beneficial interest in 40,000 Ordinary Shares. Following this
transaction Mr Immelman, and persons connected to him, have an
interest in DXS Ordinary Shares of 6,563,829 Ordinary Shares
representing 10.25% of the issued share capital of the Company.
|
1 |
Details of the person discharging managerial
responsibilities / person closely associated |
|
a) |
Name |
David Immelman |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Chief Executive |
|
b) |
Initial notification /Amendment |
Initial |
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
|
a) |
Name |
DXS INTERNATIONAL PLC |
|
b) |
LEI |
2138001R1KEUWTXEVJ44 |
|
4 |
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted |
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.33p each |
|
|
|
|
Identification code |
ISIN GB00B2Q6HZ92 |
|
|
|
|
b) |
Nature of the transaction |
Issue of new shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
2.5p |
40,000 |
|
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|
|
|
|
- Aggregated volume |
|
|
|
|
|
- Price |
|
|
|
|
|
e) |
Date of the transaction |
4 December 2023 |
|
f) |
Place of the transaction |
Aquis Stock Exchange |
The Directors of DXS International plc accept
responsibility for this announcement.
Enquiries:
| David
Immelman (Chief
Executive)DXS International plc |
01252 719800david@dxs-systems.com |
| Wrecclesham
HouseWrecclesham RoadFarnhamSurreyGU10 4PS |
|
|
www.dxs-systems.co.uk |
|
| Corporate
Advisor |
|
| David
PapworthCity & Merchant |
0207 101 7676 |
| Corporate
Broker |
|
| Hybridan
LLPClaire Louise Noyce |
020 3764 2341 |
Note to Editors:
DXS International presents up to date treatment
guidelines and recommendations, from Clinical Commissioning Groups
and other trusted NHS sources, to doctors, nurses and pharmacists
in their workflow and during the patient consultation. This
effective clinical decision support ultimately translates to
improved healthcare outcomes delivered more cost effectively which
should significantly contribute towards the NHS achieving its
projected efficiency savings.
Grafico Azioni DXS (AQSE:DXSP)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni DXS (AQSE:DXSP)
Storico
Da Nov 2023 a Nov 2024
